Astrazeneca plc has added a dual PDE3/4 inhibitor candidate to its chronic obstructive pulmonary disease (COPD) portfolio via a deal worth up to $2.1 billion with Chia Tai Tianqing Pharmaceutical Group Co. Ltd., a Sino Biopharmaceutical Ltd. subsidiary. Read More
While the emergence of immune checkpoint inhibitor (ICI) therapy in recent years has significantly improved cancer outcomes, some patients have been unable to experience the full therapeutic benefits of ICIs due to significant gastrointestinal inflammation linked to treatment. Seres Therapeutics Inc. is looking to change that with its live biotherapeutic candidate, SER-155, offering impressive findings from phase I data in ICI-related enterocolitis, or irEC. Read More
Of all the U.S. SEC’s recent proposed rules to make going, and staying, public more attractive, perhaps the most beneficial for biopharma and med-tech startups is the amendment that would give public companies the flexibility to file semi-annual rather than quarterly reports, Ben Bradford, head of external affairs at Massbio, told BioWorld. Read More
Pending talks with regulators, Satellos Bioscience Inc. may seek accelerated approval in Duchenne muscular dystrophy (DMD) for SAT-3247, which yielded positive results in the adult phase II Trailhead study. Shares of Toronto-based Satellos (NASDAQ:MSLE) closed July 8 at $8.98, up 77 cents, or 9.4%, after the firm made public six-month interim data from Trailhead. Read More
Island Pharmaceuticals Ltd. has secured government and ethics approvals to deploy its investigational antiviral galidesivir in patients infected during the escalating Bundibugyo Ebola outbreak in Africa, giving the small Australian biotech a rare opportunity to collect prospective human data in an active filovirus emergency. Read More
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience meeting – a symposium on ectodomain shedding showcased how soluble synaptic proteins are emerging as both biomarkers and therapeutic candidates for disorders ranging from autism to schizophrenia. Read More
After decades of clinical research and false starts, have Brain-Computer Interface (BCI) systems finally arrived? With developments accelerating in the field, BioWorld's special series explores the advancements in the space, looking at the implanted technologies, their potential to transfer care, what’s driving investor interest and the challenges ahead. Read More
New hires and promotions in the biopharma and med-tech industries, including: Akari, Amplia, Biovica, Demerx, Eupraxia, Imagenebio, Jupiter, Kymera, Levicept, Longeveron, Paradromics, Stipple, Uniquity, Vascular Perfusion Solutions. Read More
Clinical updates for biopharma and med tech, including data readouts and publications: Compass, HMNC, Italfarmaco, ITM, Kailera, Oncotelic, Teva, Turn, Tvardi, Vaxart, Volitionrx. Read More
Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Alamar, Alcon, Bio-Rad, Biocartis, Biocytogen, Cresilon, Corza, Discovery, Ethos, GTCR, Incite Genomics, Novo Nordisk, Praxis, Remagine, Rxsight, Vivani, Whitehawk, Xeltis. Read More
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Agios, Beckman, Emmecell, Genmab, Movmedix, Organogenesis, Revolution, Saol. Read More
